Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  Eisai Co., Ltd    4523   JP3160400002

News SummaryMost relevantAll newsSector newsTweets

Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25 Mg in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
10/13/2017 | 03:31pm CEST

TOKYO, Oct. 13 -- Eisai issued the following news release:

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), Toyama Chemical Co., Ltd. of the Fujifilm Group (Headquarters: Tokyo, President: Junji Okada, "Toyama Chemical") and Taisho Pharmaceutical Co., Ltd. (Headquarters: Tokyo, Chief Executive Officer: Shigeru Uehara, "Taisho Pharmaceutical") announced today that Eisai will acquire the marketing authorization and take over the marketing activities for anti-rheumatic agent KOLBET (R) Tablets 25mg (generic name: iguratimod), based on an agreement between the companies. Currently, Toyama Chemical holds the marketing authorization and manufactures the agent, while Taisho Pharmaceutical hold the rights to market the agent, which it exercises through Taisho Toyama Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Kenichi Fujita, "TaishoToyama").

Transfer of the marketing authorization for the agent from Toyama Chemical to Eisai and transfer of the marketing activites from Taisho Pharmaceutical and TaishoToyama to Eisai are scheduled to take place on January 1, 2018. Toyama Chemical will continue to manufacture the agent.

Iguratimod is an active ingredient developed by Toyama Chemical. It is a Disease Modifying Anti- Rheumatic Drug (DMARD) which exhibits an anti-rhematic effect mainly by suppressing production of immunoglobulin and inflammatory cytokines. Iguratimod demonstrated efficacy as monotherapy in a domestic clinical study for rheumatoid arthritis patients, and in a combination study with methotrexate (MTX), the standard of care, it was the first orally-administered anti-rheumatic drug in Japan to demonstrate efficacy as an add-on therapy to MTX in patients who responded inadequately to MTX monotherapy.

Iguratimod is sold by Eisai and Taisho Toyama under the brand names Careram (R) Tablets 25 mg and KOLBET (R) Tablets 25 mg, respectively, with both companies working to market the product and provide information on its proper use. Based on this transfer of the marketing authorization and marketing activities, Eisai will be the sole distributor of iguratimod in Japan.

Eisai, Toyama Chemical, Taisho Pharmaceutical and TaishoToyama will cooperate to ensure the smooth transfer of the marketing authorization and marketing activities for KOLBET tablets.

Targeted News Service, source News Service

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EISAI CO., LTD
10/17 Eisai co. - transfer of rights to anti rheumatic agent kolbet tablets 25 mg i..
10/13 Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25 Mg in Japan
10/13 EISAI : Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan
10/12 EISAI : H3 Biomedicine Granted Orphan Drug Designation of H3B - 6527 for Treatme..
10/11 EISAI : Small and Easy to Take, Just One Tablet Per Dose Eisai to Launch 'Onji-n..
10/11 EISAI : Small and easy to take, just one tablet per dose eisai to launch 'onji n..
10/11 EISAI : Small and Easy to Take, Just One Tablet per Dose Eisai to Launch "Onji-N..
10/06 EISAI : And biotoscana sign exclusive licensing agreement for latin america
10/05 EISAI : Sato pharmaceutical and eisai to co-promote new oral antifungal agent co..
10/05 EISAI : and Grupo Biotoscana Sign Exclusive Licensing Agreement for the Commerci..
More news
News from SeekingAlpha
09/28 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 28, 2017
09/26 FDA accepts Eisai's marketing application for Lenvima for first-line liver ca..
09/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 24, 2017
09/20 YOUR DAILY PHARMA SCOOP : Geron's Growth Potential, Ipsen's Xarmelo Approval, GS..
09/19 Eisai's lenvatinib on par with sorafenib in late-stage liver cancer study
Financials ( JPY)
Sales 2018 566 B
EBIT 2018 -
Net income 2018 37 507 M
Debt 2018 11 351 M
Yield 2018 2,50%
P/E ratio 2018 45,36
P/E ratio 2019 48,61
EV / Sales 2018 3,17x
EV / Sales 2019 3,18x
Capitalization 1 783 B
Duration : Period :
Eisai Co., Ltd Technical Analysis Chart | 4523 | JP3160400002 | 4-Traders
Technical analysis trends EISAI CO., LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 11
Average target price 6 645  JPY
Spread / Average Target 11%
EPS Revisions
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer & Chief IR Officer
Hideki Hayashi Chief Information Officer
Nobuo Deguchi Director
Noboru Naoe Director
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD-10.38%15 768
JOHNSON & JOHNSON22.11%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER10.31%213 372